

Driven by its growth, and the pharmaceutical expertise of its founding directors and a structured team, PHARMASIMPLE’s ambition is to become one of the leaders in France and in Europe.
Since its creation in 2010, PHARMASIMPLE has been supporting its hypergrowth model by preserving a positive EBITDA. PHARMASIMPLE generated a revenue of € 6.8M in 2015, an increase of 51% from 2014, with an EBITDA of € 148K.
ATOUT CAPITAL accompanied PHARMASIMPLE for the listing of its securities on Free Market of EURONEXT Paris under the direct listing procedure. 30,000 shares, representing 3.2 % of its share capital, were offered to the market. The demand was significant, with a service rate lower than 100%. PHARMASIMPLE shares have been listed since November 17th 2016 (ISIN BE0974302342/Ticker: MLPHA).
This first step should allow PHARMASIMPLE to settle into the stock markets before a further fund raising aiming to finance its growth and to prepare its transfer to Alternext.
ATOUT CAPITAL (CIF n° E 001758 with the AMF) is a financial services consulting firm providing services to small and medium-sized businesses. It specializes in equity financing operations (IPO, private placements, secondary offerings), M&A (takeover bids, industrial transactions, LBO), debt financing (IBO, bank and private) and insolvency proceedings.




